Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells

Sansan Chen; Xinglu Chen; Gui’e Xie; Yue He; Daoyu Yan; Dianpeng Zheng; Shi Li; Xinyang Fu; Yeping Li; Xiang Pang; Zhiming Hu; Hongwei Li; Wanlong Tan; Jinlong Li

doi:10.18632/oncotarget.9616

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells

Sansan Chen _, Xinglu Chen, Gui’e Xie, Yue He, Daoyu Yan, Dianpeng Zheng, Shi Li, Xinyang Fu, Yeping Li, Xiang Pang, Zhiming Hu, Hongwei Li, Wanlong Tan and Jinlong Li

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:40362-40376. https://doi.org/10.18632/oncotarget.9616

Metrics: PDF 2068 views | HTML 2567 views | ?

Abstract

Sansan Chen1,2,*, Xinglu Chen2,*, Gui’e Xie3,*, Yue He2, Daoyu Yan2, Dianpeng Zheng2, Shi Li1, Xinyang Fu1, Yeping Li1, Xiang Pang1, Zhiming Hu2, Hongwei Li2, Wanlong Tan1, Jinlong Li2

1Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

2Institute of Biotherapy, School of Biotechnology, Southern Medical University, Guangzhou, Guangdong, China

3KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, Guangdong, China

*These authors contributed equally to this work

Correspondence to:

Jinlong Li, email: [email protected]

Wanlong Tan, email: [email protected]

Hongwei Li, email: [email protected]

Keywords: Cdc6, ATR, cisplatin-resistance, bladder cancer

Received: January 07, 2016 Accepted: May 08, 2016 Published: May 26, 2016

ABSTRACT

High activation of DNA damage response is implicated in cisplatin (CDDP) resistance which presents as a serious obstacle for bladder cancer treatment. Cdc6 plays an important role in the malignant progression of tumor. Here, we reported that Cdc6 expression is up-regulated in bladder cancer tissues and is positively correlated to high tumor grade. Cdc6 depletion can attenuate the malignant properties of bladder cancer cells, including DNA replication, migration and invasion. Furthermore, higher levels of chromatin-binding Cdc6 and ATR were detected in CDDP-resistant bladder cancer cells than in the parent bladder cancer cells. Intriguingly, down-regulation of Cdc6 can enhance sensitivity to CDDP both in bladder cancer cells and CDDP-resistant bladder cancer cells. Cdc6 depletion abrogates S phase arrest caused by CDDP, leading to aberrant mitosis by inactivating ATR-Chk1-Cdc25C pathway. Our results indicate that Cdc6 may be a promising target for overcoming CDDP resistance in bladder cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9616

Publication Alerts

Research Papers:

Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells

Abstract